Oral treatment with the selective TYK2 inhibitor, BMS‐986165 was also efficacious and ameliorated progression in murine models of spondylarthritis, lupus nephritis, inflammatory bowel disease, and autoimmune diabetes [46, 56]. The gene discussed is TYK2; the disease is inflammatory bowel disease.